

Make CONTRAVE part of their weight management journey

Now available in pharmacies!



Introducing CONTRAVE...

CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

- ≥30 kg/m² (obese) or
- ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia).




CONTRAVE recommended daily dose is two tablets BID^{1*}

In order to minimize the risk of seizures, the maximum



CONTRAVE dosing should be escalated according to the following schedule:



The **maximum** recommended dose is **32 mg / 360 mg per day** (two tablets twice daily).

Response to therapy should be evaluated after 12 weeks at the maintenance dosage. If a patient has not lost at least 5% of baseline body weight, discontinue CONTRAVE, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.

Dosage adjustments are required in subjects with hepatic impairment (maximum dose 1 tablet in the morning in mild or moderate hepatic impairment) or renal impairment (maximum dose 2 tablets, one in the morning and one in the evening in moderate or severe renal impairment), and with concomitant use of CYP2B6 inhibitors (maximum dose 2 tablets, one in the morning and one in the evening). CONTRAVE should not be taken with a high-fat meal. **The tablets should not be cut, chewed, or crushed.**

Consult the Product Monograph at <u>https://pdf.hres.ca/dpd_pm/00043849.PDF</u> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-361-4261.



* Please consult the Product Monograph for complete dosage and administration information.

Reference: 1. CONTRAVE Product Monograph. Valeant Canada LP, February 12, 2018.



CONTRAVE and the CONTRAVE logo are registered trademarks of Orexigen Therapeutics, Inc. and are used under license by Valeant Pharmaceuticals International, Inc. or its affiliates. © Valeant Canada LP, Laval, Québec H7L 4A8 - All rights reserved.



